There are currently 1572 clinical trials in Dallas, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Texas Southwestern Medical Center, UT Southwestern Medical Center, UT Southwestern/Simmons Cancer Center-Dallas and GSK Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Study to Evaluate Biological & Clinical Effects of Significantly Corrected CFTR Function in Infants & Young Children
NCT04509050
Recruiting
This is a two-part, multi-center, prospective longitudinal, exploratory study of highly effective cystic fibrosis transmembrane conductance regulator (CFTR) modulators and their impact on children with cystic fibrosis (CF).
Gender:
All
Ages:
5 years and below
Trial Updated:
05/04/2023
Locations: University of Texas Southwestern / Children's Health, Dallas, Texas
Conditions: Cystic Fibrosis
Register for Updates
Liver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs
NCT04613921
Recruiting
Management of ACLF is mainly supportive. The poor outcomes lead physicians to consider liver transplantation as an option, even if controversial. In sicker recipients, LT results in immediate survival, but poor medium-term survival rates in some studies. The scarcity of deceased donors obliges to maximize LT success. Alternative strategies, as living-donor LT, should be explored. LDLT has impressive results in Eastern centers, but it is restrained in Western countries, due to potential life-thre... Read More
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
05/03/2023
Locations: Baylor College of Medicine (Scott & White), Dallas, Texas
Conditions: Liver Diseases, Liver Cirrhosis, Acute-On-Chronic Liver Failure, Liver Transplant; Complications
Register for Updates
Study of ORIC-944 in Patients With Metastatic Prostate Cancer
NCT05413421
Recruiting
The purpose of this study is to establish recommended Phase 2 dose (RP2D) and/or maximum tolerated dose (MTD) and preliminary antitumor activity of ORIC-944 in patients with metastatic prostate cancer.
Gender:
Male
Ages:
18 years and above
Trial Updated:
04/28/2023
Locations: Urology Clinics of North Texas, Dallas, Texas
Conditions: Metastatic Prostate Cancer, Neuroendocrine Prostate Cancer
Register for Updates
Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)
NCT04174157
Recruiting
Spinal muscular atrophy (SMA) is a neurogenetic disorder caused by a loss or mutation in the survival motor neuron 1 gene (SMN1) on chromosome 5q13, which leads to reduced SMN protein levels and a selective dysfunction of motor neurons. SMA is an autosomal recessive, early childhood disease with an incidence of 1:10,000 live births. SMA is the leading cause of infant mortality due to genetic diseases. Until recently, the mainstay of treatment for these patients was supportive medical care. Howe... Read More
Gender:
All
Ages:
All
Trial Updated:
04/18/2023
Locations: Children's Health, Dallas, Texas
Conditions: Spinal Muscular Atrophy (SMA)
Register for Updates
Comparison of Methods of Pulmonary Blood Flow Augmentation in Neonates: Shunt Versus Stent (The COMPASS Trial)
NCT05268094
Recruiting
COMPASS is a prospective multicenter randomized interventional trial. Participants with ductal-dependent pulmonary blood flow will be randomized to receive either a systemic-to-pulmonary artery shunt or ductal artery stent. Block randomization will be performed by center and by single vs. two ventricle status. Participants will be followed through the first year of life.
Gender:
All
Ages:
Between 1 day and 30 days
Trial Updated:
04/12/2023
Locations: UT Southwestern Medical Center, Dallas, Texas
Conditions: Congenital Heart Disease in Children
Register for Updates
Screening for High Frequency Malignant Disease
NCT05117840
Recruiting
The SHIELD (Screening for High Frequency Malignant Disease) study is a prospective, observational, multi-site basket design trial without randomization. The primary objective of the study is to evaluate the sensitivity and specificity of a blood-based GuardantLUNAR-2 test to detect high frequency cancer in screen-relevant populations.
Gender:
All
Ages:
Between 50 years and 80 years
Trial Updated:
04/10/2023
Locations: Southwest Family Medicine Associates, Dallas, Texas +1 locations
Conditions: Lung Cancer
Register for Updates
Early Routine Bowel Preparation for Suspected Acute Diverticular Bleeding
NCT05170945
Recruiting
This investigation will utilize both a five-year retrospective analysis and a two-year prospective investigation. Variables including age; gender; presence of anticoagulation medication; hospital length of stay; total transfused red blood cell units; presence of heart failure, chronic kidney disease, or lung disease; history of diverticular disease; whether colonoscopy was performed; if therapeutic hemostasis was performed during colonoscopy; and information regarding prior colonoscopies in the... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/30/2023
Locations: Methodist Dallas Medical Center, Dallas, Texas
Conditions: Diverticular Bleeding
Register for Updates
BP1001-A in Patients With Advanced or Recurrent Solid Tumors
NCT04196257
Recruiting
This is a phase I, open-label, study of BP1001-A in participants with advanced or recurrent solid tumors. The dose escalation phase will determine the safety and the maximum tolerated dose (MTD) or maximum administered dose (MAD) of BP1001-A as a single agent. After the MTD or MAD of BP1001-A is established, the dose expansion phase will commence and determine the safety, toxicity and response of BP1001-A in combination with paclitaxel.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/27/2023
Locations: Mary Crowley Cancer Research, Dallas, Texas
Conditions: Solid Tumor, Adult, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Endometrial Cancer, Peritoneal Cancer, Solid Tumor
Register for Updates
IMM2902, a HER2/SIRPα Bispecific mAb-Trap Antibody-receptor Fusion Protein, in Patients With HER2-expressing Advanced Solid Tumors
NCT05076591
Recruiting
This trial is a first-in-human, open label, multi-center, dose escalation phase 1a study followed by a disease-specific dose expansion phase 1b study to evaluate the safety, efficacy, and pharmacokinetics (PK) of IMM2902, a HER2/SIRPα bispecific mAb-Trap antibody-receptor fusion protein, in patients with HER2-expressing advanced solid tumor.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/27/2023
Locations: Mary Crowley Cancer Research, Dallas, Texas
Conditions: Advanced Solid Tumor, Advanced Breast Cancer, Advanced Gastric Cancer
Register for Updates
Blue Light Cystoscopy With Cysview® Registry
NCT02660645
Recruiting
Registry study to gather more information on the current use of Blue Light Cystoscopy with Cysview (BLCC) in urologists' practices.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/27/2023
Locations: UT Southwestern, Dallas, Texas
Conditions: Bladder Cancer
Register for Updates
Immuno-bridging and Broadening Study of a Whole, Inactivated COVID-19 Vaccine BBV152 in Healthy Adults
NCT05258669
Recruiting
A randomized, observer-blind, placebo-controlled immuno-bridging, and broadening study to demonstrate the equivalence of the immune response between participants enrolled in Phase 3 efficacy trial in India and demographically diverse healthy adult participants in the US which matched in age and vaccine formulation setting to whom those efficacy results are extrapolated; and to assess the broadening of the BBV152 in participants who previously received two shots of messenger ribonucleic acid (mRN... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/24/2023
Locations: PRX Research, Dallas, Texas
Conditions: COVID-19
Register for Updates
LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis
NCT02205762
Recruiting
The LCH-IV is an international, multicenter, prospective clinical study for pediatric Langerhans Cell Histiocytosis LCH (age < 18 years).
Gender:
All
Ages:
18 years and below
Trial Updated:
03/21/2023
Locations: Children's Medical Center Dallas, UT Southwestern, Dallas, Texas
Conditions: Langerhans Cell Histiocytosis
Register for Updates